Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
- 1 November 2003
- journal article
- clinical trial
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 13 (6) , 735-740
- https://doi.org/10.1111/j.1525-1438.2003.13602.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Developmental Chemotherapy and Management of Recurrent Ovarian CancerJournal of Clinical Oncology, 2003
- Abstracts Presented for the Thirty-Fourth Annual Meeting of the Society of Gynecologic OncologistsGynecologic Oncology, 2003
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian CancerJournal of Clinical Oncology, 2000
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2000
- Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Carboplatin versus cisplatinAnnals of Oncology, 1993